ModifiedPremera BluecrossPolicy 7.01.101

Surgical Treatment of Snoring and Obstructive Sleep Apnea Syndrome

Defines medical necessity, site-of-service, and coding for selected elective surgical procedures for OSA and snoring, and specifies coverage criteria for interventions including palatopharyngoplasty, hypoglossal nerve stimulation, hyoid suspension, and related procedures for Premera Blue Cross members.

Policy Summary

PayerPremera Bluecross

PolicySurgical Treatment of Snoring and Obstructive Sleep Apnea Syndrome

Policy CodePolicy 7.01.101

Change TypeCriteria updated: HNS device/age/BMI limitsinvestigational statuses and coding updates

Effective DateMar 1, 2026

Next Review Date

Key ActionObtain prior authorization and document CPAP failure/intolerance, AHI, BMI, device name and DISE findings when requesting hypoglossal nerve stimulation.

SourceLink

POLICY UPDATE CHANGES

Policy statement is added that HNS using other FDA-approved devices (e.g., Genio) is considered investigational for treating clinically significant OSA syndrome.

Submucosal cryolysis is considered investigational.

BMI criteria for hypoglossal nerve stimulation (HNS) in adults updated from ≤40 kg/m² to ≤35 kg/m²; age criteria for adults changed from ≥22 to ≥18; age for individuals with Down syndrome changed from 10–21 to 13–18.

Site of Service Ambulatory Service Center (ASC) criteria added, effective November 7, 2025.

New HCPCS codes C8007-C8009 and C8011-C8013 added effective April 1, 2026.

≤35Current BMI limit for HNS

18+Minimum adult age for HNS

15–100

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

AHI criteria (Inspire)

InvestigationalStatus: Genio / other HNS

InvestigationalStatus: Submucosal cryolysis

04/01/26New HCPCS effective

Coverage Criteria and Policy Stance

Medically necessary surgical interventions and site-of-service criteria

Covered when ALL of the following site-of-service and procedure-specific requirements are met as specified below

Site of service: Procedure must be performed in a medically necessary site of service: preferred is Ambulatory Surgical Center (ASC) when appropriate; off-campus outpatient hospital or on-campus outpatient hospital may be considered medically necessary if no qualifying ASC within 30 miles, physician lacks privileges at ASC, ASC guideline prohibits use due to health/weight, patient is <=18 years, procedure is concurrent with an additional service requiring hospital outpatient department, or patient has increased clinical risk.

See detailed risk criteria (ASA III+, recent MI, NYHA III/IV, poorly controlled HTN, recent stroke, MELD>8, COPD FEV1<50%, poorly controlled asthma, ESRD on dialysis, morbid obesity BMI>=50, pregnancy, bleeding disorder requiring replacement products, anticipated transfusion).

Increased clinical risk exceptions for hospital outpatient/inpatient: Increased risk includes ASA classification III or higher; recent myocardial infarction (<3 months); NYHA class III or IV heart failure; poorly controlled or resistant hypertension; recent cerebrovascular accident (<3 months); increased risk for cardiac ischemia (recent stent/angioplasty); symptomatic arrhythmia despite medication; significant valvular heart disease; advanced liver disease (MELD >8); COPD with FEV1 <50%; poorly controlled asthma (FEV1 <80% despite treatment); end-stage renal disease on dialysis; morbid obesity (BMI >=50); pregnancy; bleeding disorder requiring factor/blood products or anticipated need for transfusion.

These conditions may justify performance in a higher-acuity site of service.

Palatopharyngoplasty (including UPPP): May be considered medically necessary for appropriately selected adults with clinically significant OSA who have failed an adequate trial of CPAP or an oral appliance.Clinically significant OSA as defined in Related Information (e.g., AHI >=15 or AHI >=5 with symptoms).

Includes uvulopalatopharyngoplasty and related palatal procedures.

Hyoid suspension, tongue modification, maxillofacial surgery (including MMA): May be considered medically necessary in appropriately selected adults with clinically significant OSA and objective documentation of hypopharyngeal obstruction who have failed an adequate trial of CPAP or an oral appliance.

Mandibular-maxillary advancement and related procedures included.

Hypoglossal nerve stimulation (Inspire device) - adults: May be considered medically necessary when ALL criteria are met: age >=18 years; AHI >=15 and <=100 with <=25% central apneas; CPAP failure (residual AHI >=15 on PAP) or CPAP intolerance (use <4 hrs/night on >=5 nights/week) or inability to tolerate CPAP; BMI <=35 kg/m2; absence of complete concentric collapse at the soft palate on drug-induced sleep endoscopy (DISE).

Device name must be documented; excludes other HNS devices (e.g., Genio) as investigational.

Hypoglossal nerve stimulation - Down syndrome (pediatric): May be considered medically necessary when ALL criteria are met: age 13–18 years; AHI >10 and <50 with <=25% central apneas after prior adenotonsillectomy; either tracheotomy or ineffective treatment with CPAP due to noncompliance/intolerance/persistent symptoms/refusal; BMI <=95th percentile for age; absence of complete concentric collapse on DISE.

Document prior adenotonsillectomy; aligns with device PMA expansions for Down syndrome subgroup.

Not medically necessary / Investigational

Not covered or investigational procedures

Not medically necessary for snoring alone: All interventions for snoring in the absence of documented OSA are considered not medically necessary, including LAUP, palatal stiffening procedures, and radiofrequency volumetric tissue reduction of the palate.

Snoring alone is not considered a medical condition.

Minimally invasive procedures investigational: The following are considered investigational for treatment of OSA/UARS: endoscopically assisted nasomaxillary expansion; LAUP or radiofrequency volumetric tissue reduction of palatal tissues; palatal stiffening procedures (e.g., CAPSO, palatal implants, sclerosing injection); radiofrequency volumetric tissue reduction of the tongue (e.g., Somnoplasty); submucosal cryolysis therapy (CryOSAA/Cryosa); tongue base suspension devices (e.g., Airvance/Repose/Encore); and other minimally invasive surgical procedures not described.

Hypoglossal nerve stimulation with devices other than Inspire (e.g., Genio) is considered investigational.

Hypoglossal Nerve Stimulation (HNS) — candidate subgroup criteria

Covered when ALL of the following are met (based on clinical study populations and expert input):

HNS selection criteria (study/expert-derived): Age >=22 years for adults (historical clinical-input criterion; policy updated in history to age >=18 in later revisions); AND diagnosed moderate to severe OSA with <25% central apneas; AND prior adequate trial of CPAP that failed or inability to tolerate CPAP; AND BMI <=32 kg/m2 in adults in the original clinical-input selection (some evidence and later policy updates include BMI up to <=35 kg/m2); AND favorable pattern of palatal collapse (absence of complete concentric collapse on DISE).

These selection elements reflect clinical trial populations and clinical expert opinion used to identify subgroups most likely to benefit from HNS.

Other minimally invasive procedures (LAUP, RF ablation, palatal stiffening, tongue base suspension, maxillary expansion) — evidence stance

Coverage stance based on available evidence:

LAUP: Evidence includes systematic reviews and RCTs showing modest AHI reductions but notable complication rates (e.g., globus, dryness, velopharyngeal insufficiency) and inconsistent success; evidence insufficient to determine net health benefit.

Reported pooled outcomes: mean AHI decrease ~6.56 events/h, low cure and success rates, and substantial complication rates.

Radiofrequency (palate/base of tongue): Sham-controlled RCTs and cohort studies show single-stage RF did not improve outcomes versus sham and multiple-session RF demonstrated inconsistent and not clinically significant AHI or functional improvements; evidence insufficient to determine net health benefit.

Some cohort data show short-term AHI and ODI improvements, but overall evidence is limited.

Palatal stiffening: Two sham-controlled RCTs with mixed results dependent on selection criteria; evidence insufficient to confirm net health benefit or to refine selection criteria.

One trial demonstrated higher success when excluding specific anatomical subgroups; additional confirmatory studies needed.

Covered surgical/device interventions

Covered when ALL of the following are met according to specialty guidance or device PMA indications:

Pediatric adenotonsillectomy: Child has OSA and clinical exam consistent with adenotonsillar hypertrophy and no contraindication to surgery; adenotonsillectomy is recommended as first-line therapy.

Based on American Academy of Pediatrics guidance.

Hypoglossal nerve stimulation (HNS) candidacy per device PMA / specialty guidance: Adult patients with moderate-to-severe OSA who have failed or cannot tolerate PAP and who meet device-specific anatomic and severity criteria (including absence of complete concentric collapse at the soft palate for some devices) and are within indicated age/BMI/AHI ranges per device PMA or supplements.AHI within device-specific range (e.g., >=15 and <=100 for Inspire; some devices list <=65); BMI within available safety data (original PMA noted BMI<=32 with supplements expanding available data up to BMI<=40; policy aligns to BMI<=35 per recent history).

Based on AAO-HNS position statements and device PMA supplements; device name and indication should be documented.

Coverage notable criteria (partial)

Selected policy criteria history and current high-level coverage stance items present in these chunks

HNS device coverage constraints (as recorded in history): Hypoglossal nerve stimulation is considered medically necessary under specified conditions but HNS using other FDA-approved devices (e.g., Genio) is considered investigational for treating clinically significant OSA syndrome.

Policy history and regulatory summaries reference Inspire as primary FDA-approved device in pivotal trials; other devices' status described as investigational within policy history.

BMI and age limits for HNS (history-recorded rule changes): Policy history documents BMI and age criteria changes: BMI limit for HNS in adults updated to <=35 kg/m2; adult minimum age changed to >=18 years; age for individuals with Down syndrome changed to 13–18 years.BMI <=35 kg/m2; age >=18 (adults); age 13–18 (Down syndrome)

These changes are recorded in policy history notes reflecting alignment with evolving evidence and PMA supplements.

Investigational procedures (history):

All interventions directed solely at snoring in the absence of documented obstructive sleep apnea (OSA) are not medically necessary. The policy explicitly lists excluded snoring-only interventions, including laser-assisted uvulopalatoplasty (LAUP), palatal stiffening procedures, and radiofrequency volumetric tissue reduction of the palate as examples of services that will be denied when there is no objective evidence of OSA. Additionally, a range of minimally invasive surgical procedures are described as investigational for treatment of OSA/UARS (see next paragraph) and therefore are excluded from coverage outside approved indications or trial settings.

This policy does not address conventional or more extensive surgical procedures. Examples specifically outside the scope include uvulopalatopharyngoplasty (UPPP), hyoid suspension, surgical modification of the tongue, maxillofacial procedures (including mandibular‑maxillary advancement), and adenotonsillectomy. Those procedures may follow different coverage rules and should be evaluated according to the appropriate surgical or specialty policies.

The National Institute for Health and Care Excellence (NICE) concluded in 2017 that the available evidence on the safety and efficacy of hypoglossal nerve stimulation (HNS) was limited in quantity and quality, and recommended that HNS be used only in the context of a clinical trial. This guidance supports a cautious approach to adoption and indicates restricted use outside of research settings in jurisdictions following NICE guidance.

Although some HNS systems have FDA approval, this policy specifies that HNS performed with FDA‑approved devices other than the Inspire system (for example, the Genio system) is considered investigational for treatment of clinically significant OSA syndrome and is not covered. The history and coverage statements were updated to add this investigational classification for non‑Inspire HNS devices.

Surgical treatment of OSA that does not meet the policy’s specified medical‑necessity criteria is considered not medically necessary and may be denied. The policy requires objective documentation of OSA and adherence to device- or procedure‑specific eligibility criteria (for example, HNS candidacy elements); procedures performed outside those criteria or performed solely for snoring without documented OSA are excluded from coverage.

Several minimally invasive procedures lack sufficient evidence to establish a net health benefit for OSA. The policy describes the evidence as insufficient for technologies including LAUP, radiofrequency (RF) volumetric reduction of the palate or tongue base, palatal stiffening procedures (including palatal implants and CAPSO), tongue base suspension, and endoscopically assisted maxillary expansion. Published RCTs, systematic reviews, and uncontrolled series report modest or inconsistent AHI and functional outcome changes and notable complication risks; therefore these procedures are designated investigational or not established as medically necessary.

Submucosal cryolysis (Cryosa System) is not FDA‑approved for treatment of OSA and is described in the regulatory and history sections as unapproved for this indication. The policy history and regulatory notes indicate that submucosal cryolysis remains investigational pending FDA approval and adequate evidence of safety and efficacy for OSA.

Consistent with the regulatory and coverage statements, submucosal cryolysis is explicitly listed as investigational for the treatment of OSA/UARS and is therefore not covered under this policy. Providers should not expect reimbursement for submucosal cryolysis for OSA when performed outside of an approved investigational protocol.

Coding, Thresholds, and Regulatory Identifiers

Covered CPT Codes (procedures listed in policy)CPT

0978T	Submucosal cryolysis therapy; soft palate, base of tongue, and lingual tonsil (new code effective 07/01/25)
0979T	Submucosal cryolysis therapy; soft palate only (new code effective 07/01/25)
0980T	Submucosal cryolysis therapy; base of tongue and lingual tonsil only (new code effective 07/01/25)
21199	Osteotomy, mandible, segmental; with genioglossus advancement
21685	Hyoid myotomy and suspension
41512	Tongue base suspension, permanent suture technique
41530	Submucosal ablation of the tongue base, radiofrequency, 1 or more sites, per session
42145	Palatopharyngoplasty (e.g., uvulopalatopharyngoplasty, uvulopharyngoplasty)
42299	Unlisted procedure, palate, uvula
42950	Pharyngoplasty (plastic or reconstructive operation on pharynx)

Covered/Related HCPCS/CPT Codes for implants and devicesmixed

64568	Open implantation of cranial nerve (e.g., vagus nerve) neurostimulator electrode array and pulse generator (used to report the Genio hypoglossal nerve stimulator and Inspire V hypoglossal nerve stimulator)
64582	Open implantation of hypoglossal nerve neurostimulator array, pulse generator, and distal respiratory sensor electrode or electrode array (used to report the Inspire IV or earlier Inspire models)
64583	Revision or replacement of hypoglossal nerve neurostimulator array and distal respiratory sensor electrode or electrode array, including connection to existing pulse generator
64584	Removal of hypoglossal nerve neurostimulator array, pulse generator, and distal respiratory sensor electrode or electrode array
C1767	Generator, neurostimulator (implantable), nonrechargeable
C1778	Lead, neurostimulator (implantable)
C8007	Open implantation of hypoglossal nerve neurostimulator array and pulse generator, not requiring insertion of a separate distal respiratory sensor electrode or electrode array (new code effective 04/01/26)
C8008	Revision or replacement of hypoglossal nerve neurostimulator array including connection to existing pulse generator (new code effective 04/01/26)
C8009	Percutaneous placement of permanent common carotid embolic protection device, including all system components and imaging guidance; bilateral (new code effective 04/01/26)
C8011	Open implantation of hypoglossal nerve(s) neurostimulator electrode array(s) and receiver, including external power source and all system components (new code effective 04/01/26)

1–10 of 14

1/2

Device regulatory identifiers mentionedmixed

K982717	Radiofrequency ablation (Somnoplasty) 510(k)
K040417	Pillar Palatal Implant 510(k)
K122391	AIRvance/Repose tongue base suspension 510(k)
K111179	Encore (PRELUDE III) tongue base suspension 510(k)
P130008	Inspire Upper Airway Stimulation PMA (original)
P240024	Genio System 2.1 PMA (Nyxoah) per document

Coding updates and added codes (history)mixed

C9727	HCPCS code added Nov 2020 (as noted in history)
64582	CPT code added 01/01/22 (history)
64583	CPT code added 01/01/22 (history)
64684	CPT code added 01/01/22 (history)
0978T	T-code added (noted in history)
0979T	T-code added (noted in history)
0980T	T-code added (noted in history)
C1607	HCPCS code added 01/01/26 then removed from this policy and moved to policy 10.01.533
C8007	HCPCS code added 04/01/26
C8008	HCPCS code added 04/01/26

1–10 of 14

1/2

inv-19: AHI/RDI thresholds for clinically significant OSA (adults) and HNS candidacy

Clinically significant adult OSA thresholdAHI or RDI ≥15 events/hour, or AHI/RDI ≥5 events/hour with one or more OSA-related symptoms (e.g., daytime sleepiness, hypertension, cardiovascular disease, or stroke)

Inspire HNS candidacy — AHI rangeAHI ≥15 and ≤100 events/hour (device PMA-based indication)

Inspire HNS candidacy — central apnea limit≤25% central apneas

inv-20: PAP failure/intolerance thresholds used for candidacy/coverage

PAP failure (objective)Residual AHI ≥15 while using PAP (often defined as ≥15–20 events/hour)

Prior Authorization, Documentation, and Operational Notes

Prior Authorization

Prior Authorization Required

Prior authorization required for surgical procedures and implantable device placement addressed by this policy. Submit a prior authorization request before scheduling UPPP, hypoglossal nerve stimulator (HNS) implantation, or other operative/device procedures listed in the policy.

Affected examples: UPPP, HNS device implantation, other surgical site procedures listed in Policy Coverage Criteria.
Check member benefits — site-of-service rules may affect authorization and coverage.

Prior Authorization

Prior Authorization Expectations for HNS

Prior authorization for hypoglossal nerve stimulation (HNS) requires documentation showing the individual meets HNS-specific selection criteria: age, objective OSA severity, central apnea percentage, prior CPAP trial or intolerance, BMI within device-specific limits, absence of complete concentric collapse on DISE, and proposed device name.

Document AHI (apnea–hypopnea index) and percent central apneas.
Document CPAP failure or intolerance per policy thresholds (residual AHI ≥15 on CPAP or CPAP use <4 hours/night for ≥5 nights/week).

Definitions and Diagnostic Thresholds

inv-44: Clinically significant OSA (adults) definition

Definition — adults (clinically significant OSA)AHI or RDI ≥15 events/hour, or AHI/RDI ≥5 events/hour with one or more OSA-related signs or symptoms (e.g., excessive daytime sleepiness, hypertension, cardiovascular disease, or stroke)

Diagnostic indices referencedAHI = events per hour of sleep; RDI = events per hour of recording time

Preferred initial therapy noteContinuous positive airway pressure (CPAP) is the preferred first-line treatment for most individuals

inv-45: Clinically significant OSA (pediatrics) definition

Definition — pediatrics (clinically significant OSA)AHI or RDI ≥5 events/hour, or AHI/RDI ≥1.5 events/hour in an individual with excessive daytime sleepiness, behavioral problems, or hyperactivity

Adenotonsillectomy note

Clinical Background and Evidence Context

Obstructive sleep apnea (OSA) results from repetitive upper‑airway collapse during sleep and is typically managed initially with continuous positive airway pressure (CPAP) or other positive airway pressure therapies. Surgery—including tissue removal procedures, maxillofacial advancement, or hypoglossal nerve stimulation—is considered when conservative therapy fails or is not tolerated. Surgical options are generally reserved for appropriately selected patients with documented, clinically significant OSA and after trials of first‑line therapies have been attempted or documented as intolerable.

Policy Changes and History

2026-03-01policy_effective_dateLatest

Policy effective date recorded in document history (most recent approval/effective entry).

2025-11-07site_of_service_added

Site of Service Ambulatory Service Center (ASC) criteria were added (Related Policy 11.01.525) and become effective November 7, 2025.

2025-09-01investigational_added

Policy Summary

PayerPremera Bluecross

PolicySurgical Treatment of Snoring and Obstructive Sleep Apnea Syndrome

Policy CodePolicy 7.01.101

Change TypeCriteria updated: HNS device/age/BMI limitsinvestigational statuses and coding updates

Effective DateMar 1, 2026

Next Review Date

Key ActionObtain prior authorization and document CPAP failure/intolerance, AHI, BMI, device name and DISE findings when requesting hypoglossal nerve stimulation.

SourceLink

On This Page

Tongue base suspension: Limited evidence (one feasibility RCT) with small sample; results similar to tongue advancement plus UPPP and insufficient to establish that tongue suspension alone improves net health outcome.

Further larger RCTs required.

Endoscopically assisted maxillary expansion: Evidence limited to uncontrolled retrospective series with short follow-up and no OSA outcome measurements; insufficient evidence to support safety and efficacy as an OSA treatment.

Reported structural expansion outcomes but no pre/post OSA outcome data.

Submucosal cryolysis and endoscopically assisted nasomaxillary expansion are listed as investigational in history entries and therefore considered not established as medically necessary.

Coding and investigational status entries in policy history reflect these determinations.

PAP intolerance — usage metric

CPAP use <4 hours/night on ≥5 nights/week

PAP failure/ intolerance — alternative wordingInability or unwillingness to use PAP (refusal) or failure to eliminate OSA (residual AHI >15 despite PAP)

inv-21: BMI threshold for HNS candidacy (device/study dependent)

BMI upper limit (current policy/history)BMI ≤35 kg/m² (policy updated in 2024–2025 to this limit)

BMI reported in some study/device selection criteriaBMI ≤32 kg/m² (earlier study/selection criterion)

Expanded PMA safety data notePMA supplement noted available safety/effectiveness data up to BMI ≤40 kg/m² for Inspire (per PMA supplement)

inv-22: AHI severity categories (adult and pediatric thresholds)

Adult severity categories — MildAHI 5 to <15 events/hour

Adult severity categories — ModerateAHI 15 to <30 events/hour

Adult severity categories — SevereAHI ≥30 events/hour

Pediatric severity categoriesChildren: Mild AHI ≥1 to 5; Moderate >5 to 10; Severe >10 events/hour

inv-23: AHI thresholds — general risk threshold and device-specific indications

General risk-treatment thresholdAHI or RDI ≥15 events/hour (identified as threshold where treatment is warranted)

Inspire device indicationAHI ≥15 and ≤100 events/hour per PMA (supplements specify ranges)

Genio System summary rangeGenio System 2.1 reported indication summary includes upper-limit ranges (e.g., ≤65 in some reports) — device-specific limits apply

inv-24: BMI threshold history and notes (PMA/expanded data)

Policy BMI history — initial PMA/earlier criterionEarlier adult HNS BMI selection reported as ≤32 kg/m² in study criteria and initial PMA

Expanded PMA and interim historyPMA supplement noted BMI upper limit with available data increased from ≤32 to ≤40 kg/m² (supplement S090) before policy alignment

Policy revision to current limitPolicy updated (2024–2025 history) to set adult HNS BMI limit to ≤35 kg/m²

inv-25: AHI values changed over time (history references)

AHI thresholds documented in policy historyPolicy history references multiple documented thresholds over time (e.g., AHI 5–14, 15–30, ≥15, >30) reflecting revisions

2019 change for HNS indication alignmentIn 2019 the HNS indication changed to AHI ≥15 from ≥20 to align with FDA

2014–2017 historical notesEarlier history entries described thresholds and conditional requirements for AHI ranges and symptom requirements

inv-26: BMI — current noted limit (≤35 kg/m²) in history

Current noted BMI limit (policy history)BMI ≤35 kg/m² (current policy limit per history entries effective 2024–2025)

Prior BMI criteria referencedPreviously BMI ≤32 kg/m² (earlier study/selection criteria)

PMA supplement safety-notePMA supplement previously reported data up to BMI ≤40 kg/m² (informational; policy uses ≤35 kg/m²)

Document BMI at or below device-specific limit (policy lists ≤35 kg/m² for Inspire; device labeling may differ).

State absence of complete concentric collapse at the soft palate on drug-induced sleep endoscopy (DISE).

Specify the HNS device to be implanted (e.g., Inspire) and include relevant FDA indication alignment.

Billing Rule

Check Prior Authorization for New HCPCS/Coding Changes

Verify prior authorization requirements for newly released HCPCS codes and other coding updates before submission. Coding updates effective April 1, 2026 may introduce new billable codes with separate PA expectations.

New HCPCS codes effective 04/01/2026: C8007-C8009, C8011-C8013 — check plan PA rules.
Recent HCPCS activity: C1607 added 01/01/2026 then removed from this policy and moved to policy 10.01.533; verify current policy assignment.
If a service/code is not listed in this policy, prior authorization may still be required under a different policy or member benefit.

Documentation Required

Severity Documentation

Document OSA severity and related objective testing. An AHI/RDI ≥15 generally indicates treatment is warranted; lack of documented severity (AHI/RDI) or central apnea proportion may result in denial.

Include the type and date of sleep study (in-lab polysomnography vs home sleep test) and reported AHI/RDI.
Report percent central apneas; HNS eligibility requires ≤25% central apneas.
For AHI 5–14, include associated symptoms or comorbidities per policy if applicable (e.g., hypertension, excessive sleepiness, ischemic heart disease).

Denial Risk

Investigational Procedures — Denial Risk

Services or devices designated investigational in this policy are subject to denial. HNS using devices other than the FDA-approved Inspire system (for the indications listed) and other investigational procedures (e.g., submucosal cryolysis, certain HNS systems such as Genio as noted) are considered investigational and not covered.

Hypoglossal nerve stimulation with other FDA-approved devices (e.g., Genio) is considered investigational for treating clinically significant OSA syndrome and may be denied.
Implantable hypoglossal nerve stimulators not meeting the stated device-specific criteria are investigational.
Procedures for snoring alone (without documented OSA) and listed investigational procedures (e.g., cryolysis) may be denied.

Documentation Required

HNS Documentation Requirements

HNS-specific documentation must be included with the authorization request: age, AHI, percent central apneas, prior CPAP trial details or CPAP intolerance, BMI, absence of complete concentric collapse on DISE, and the specific device name; for Down syndrome patients include documentation of prior adenotonsillectomy.

Age of individual and indication (adult vs adolescent/Down syndrome subgroup).
Objective sleep study results: AHI and percent central apneas.
CPAP history: documented trial, residual AHI on CPAP, average nightly use (hours/night and nights/week) or documented intolerance.
BMI value and date measured.
DISE findings documenting absence of complete concentric collapse at the soft palate.
Name and model of the device proposed for implantation.
If Down syndrome: documentation of prior adenotonsillectomy and continued OSA.

Documentation Required

Suggested Documentation for HNS Candidate Selection

Suggested supporting documentation to demonstrate the individual is an appropriate HNS candidate, based on clinical input and device labeling, should be included to expedite review and align with clinical selection criteria.

Clinical assessment describing pattern of palatal collapse (favorable/non-concentric) or DISE report.
History of conservative therapy attempts: CPAP and oral appliance trials with durations and objective adherence data.
Relevant comorbidities and prior surgical history (e.g., prior adenotonsillectomy in adolescents).
Anthropometrics and weight-loss efforts if BMI near device threshold.

Documentation Required

Documentation of Diagnostic and Criteria Alignment

Include a clear diagnostic timeline and alignment of diagnostic criteria when submitting requests. If prior diagnostic criteria or thresholds changed over time, document which criteria were used and dates of testing to avoid misinterpretation.

Provide dates of sleep studies and any repeat testing showing progression or persistence of OSA.
If prior policies/criteria changed (e.g., AHI thresholds), note which version applied at time of testing.
Attach prior authorization denials or prior medical records explaining CPAP failure/intolerance for continuity.

Step Therapy

Required Trial of CPAP or Oral Appliance Before Surgery

Prior to considering surgery or implantable devices, document a trial of CPAP or a mandibular advancement oral appliance unless contraindicated. The policy requires evidence of an adequate trial of CPAP or oral appliance for many surgical options and for adult HNS candidates.

CPAP trial documentation should include device settings, residual AHI on therapy, objective adherence data (hours/night and nights/week), and reasons for intolerance if applicable.
If an oral appliance was used, include fitting records, titration notes, and objective outcomes when available.

Note

Preferred Initial Therapies Before Surgical Options

Preferred initial therapies should be exhausted before elective surgical options: positive airway pressure (PAP) therapy for adults and adenotonsillectomy as first-line for children with adenotonsillar hypertrophy. Surgery is considered when initial therapies fail or are not tolerated.

Adults: PAP (CPAP/BiPAP) remains the preferred initial therapy; document attempts at PAP adherence and management of side effects.
Pediatrics: Adenotonsillectomy is first-line when adenotonsillar hypertrophy is present; refer to CPAP if OSA persists postoperatively.

Documentation Required

Pediatric Treatment Sequencing

For pediatric patients, follow pediatric sequencing: adenotonsillectomy is first-line for children with adenotonsillar hypertrophy; if OSA persists after surgery or surgery is not appropriate, refer for CPAP management and document further steps.

Document adenotonsillectomy indication and operative report when applicable.
If persistent OSA after adenotonsillectomy, include sleep study results and documentation of CPAP referral and trial.

Documentation Required

Prior CPAP Therapy Documentation

When documenting prior CPAP therapy for HNS consideration, include specific thresholds used to define CPAP failure per policy: residual AHI on CPAP ≥15 or CPAP use <4 hours/night for ≥5 nights per week, or documented inability to tolerate CPAP.

Provide device download reports showing nightly usage and residual AHI while on CPAP.
If CPAP was discontinued for intolerance, include clinician notes describing adverse effects, noncompliance reasons, or refusal.

Adenotonsillectomy may be considered medically necessary in pediatric individuals with clinically significant OSA and hypertrophic tonsils

AHI interpretation in childrenPediatric AHI thresholds differ from adults and are lower for defining severity

inv-46: AHI / Severity categories

AHI — adult categoriesMild: 5–<15; Moderate: 15–<30; Severe: ≥30 events/hour

AHI — pediatric categoriesChildren: Mild ≥1–5; Moderate >5–10; Severe >10 events/hour

AHI definitionAHI is the average number of apneas or hypopneas per hour of sleep

inv-47: RERA / RDI / REI definitions

RERA definitionRespiratory event-related arousal (RERA): event ≥10 seconds associated with flattening of nasal pressure waveform and/or increased respiratory effort, terminating in an arousal

RDI definitionRespiratory Disturbance Index (RDI): number of apneas, hypopneas, or RERAs per hour of sleep time

REI definitionRespiratory Event Index (REI): events per hour of monitoring time, used in home sleep studies when EEG-derived sleep time is not available

inv-48: PAP failure / intolerance definitions

PAP failure — typical definitionUsually defined as an AHI ≥15–20 events/hour while using PAP (residual AHI ≥15 is used in policy criteria)

PAP intolerance — usage-based definitionCPAP use <4 hours/night on ≥5 nights/week, or refusal to use PAP

Policy candidacy requirementHNS candidacy requires documented CPAP failure (residual AHI ≥15 or usage <4 hrs/night on ≥5 nights/week) or inability to tolerate CPAP

inv-49: AHI/RDI label (Apnea–Hypopnea Index / Respiratory Disturbance Index)

AHI/RDI labelAHI = Apnea–Hypopnea Index; RDI = Respiratory Disturbance Index

Usage in diagnosisBoth AHI and RDI are used to quantify sleep-disordered breathing severity; RDI may include RERAs

REI noteREI used as alternative in home studies when EEG-derived sleep time is not available

inv-50: PAP failure/intolerance — alternative wording/thresholds in definitions

Alternative PAP failure wordingPAP failure described as inability to eliminate OSA (residual AHI >15 despite PAP)

Alternative PAP intolerance wordingPAP intolerance described as inability or unwillingness to use PAP (usage <4 hrs/night on ≥5 nights/week or refusal)

Clinical implicationDocumentation of prior CPAP attempts, objective residual AHI, or documented intolerance is required for some surgical/device candidacy decisions

inv-51: AHI abbreviation reference

AHI abbreviationAHI = Apnea–Hypopnea Index

Definition summaryAHI is the total number of apneas and hypopneas per hour of recorded sleep

Related indicesRDI and REI are related indices used in different recording contexts

Policy history added statement that submucosal cryolysis is considered investigational and related coding updates were added.

2024-10-01policy_replacement

Policy 7.01.101 was deleted and replaced with 7.01.554 (approved September 10, 2024) with updates including BMI and age criteria for HNS.

2023-11-01hns_bmi_expansion

Interim review updated HNS adult BMI criterion from ≤32 kg/m² to ≤40 kg/m² to align with expanded FDA indication (approved 2023-06-08).

2022-08-01cpap_failure_threshold_change

Interim review changed CPAP failure definition for HNS from residual AHI ≥20 to ≥15 for consistency with other policies.

2022-01-01coding_update

Coding update added new CPT codes 64582, 64583, and 64684 and updated description of CPT 64568.

2019-02-01initial_hns_necessity_recorded

Annual review approved January 8, 2019 noted hypoglossal nerve stimulation considered medically necessary under specified conditions.

The policy history includes coding updates and additions. Notably, several HCPCS codes (C8007–C8009 and C8011–C8013) were added effective April 1, 2026. Earlier history entries also note coding changes (for example, CPT addenda in 2022 and HCPCS updates in 2026). Providers should verify prior authorization and billing requirements for these new codes with the payer.